← Back to Clinical Trials
Recruiting NCT06365892

NCT06365892 Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06365892
Status Recruiting
Phase
Sponsor University of California, San Francisco
Condition Adolescent Idiopathic Scoliosis (AIS)
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2024-07-01
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
open-label placeboTreatment as usual

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 64 participants in total. It began in 2024-07-01 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the effects of conditioning with open-label placebos on standard postoperative treatment for patients undergoing surgery for idiopathic scoliosis in a randomized controlled, 6-week trial with 64 AIS patients randomly assigned to one of two arms: Open-label Placebo (COLP) + treatment as usual TAU / TAU control. The study involves collecting data from your child's medical record. At each regular clinic visit, the patient clinical data will be collected by the research coordinator. Surveys will be collected including:• PROMIS for the age group 10 to 18 years.

Eligibility Criteria

Inclusion Criteria: To be eligible for enrollment, patients must meet all of the following inclusion criteria: 1. Diagnosis of idiopathic spine deformity. 2. Age \>10 and \<18 years. 3. Primary procedure. 4. Guardian provides signed and dated informed consent and understand the nature of the study sufficiently to allow completion of all study assessments. 5. Patient provides assent. 6. Fusion and fusionless instrumented spine surgery. Exclusion Criteria: If any of the following exclusion criteria are met, the patient is not eligible for the study: 1. Non-idiopathic scoliosis, such as neuromuscular or syndrome. 2. Revision procedure. 3. Self-reported pregnancy or planned pregnancy within the next two months. 4. Have a history of drug, excluding nicotine or caffeine, or alcohol abuse within 2 years of entry into the study 5. Already taking opioids. 6. Abnormal physical examination. 7. Inability to speak or read English 8. Patient declines participation.

Contact & Investigator

Central Contact

Mohammad Diab, MD

✉ mohammad.diab@ucsf.edu

📞 415-514-1519

Principal Investigator

Mohammad Diab, MD

PRINCIPAL INVESTIGATOR

University of California, San Francisco

Frequently Asked Questions

Who can join the NCT06365892 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Adolescent Idiopathic Scoliosis (AIS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06365892 currently recruiting?

Yes, NCT06365892 is actively recruiting participants. Contact the research team at mohammad.diab@ucsf.edu for enrollment information.

Where is the NCT06365892 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT06365892 clinical trial?

NCT06365892 is sponsored by University of California, San Francisco. The principal investigator is Mohammad Diab, MD at University of California, San Francisco. The trial plans to enroll 64 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology